News

CURE2d
FDA Grants Priority Review to TAR-200 for Bladder Cancer Subset
FDA grants priority review to TAR-200, which demonstrated an 82% complete response in high-risk bladder cancer unresponsive ...
Guselkumab demonstrates superior efficacy in clinical trials, offering new hope to Crohn's disease patients
In a major advance for patients with Crohn's disease, a new study led by researchers at Mount Sinai Health System found that ...
Drug Delivery Business2d
Johnson & Johnson wins FDA priority review for drug delivery system
(NYSE:JNJ) announced today that the FDA granted priority review to a new drug application (NDA) for its TAR-200.
Targeted Oncology2d
FDA Grants Priority Review to NDA of TAR-200 in BCG-Unresponsive NMIBC
The FDA prioritizes TAR-200 for treating high-risk bladder cancer, showcasing promising phase 2b study results and innovative ...
J&J gets FDA priority review for drug releasing system for bladder cancer
Johnson & Johnson (JNJ) gets FDA priority review for TAR-200 gains, a drug releasing system targeting bladder cancer. Read ...
Johnson & Johnson Gets Speedy FDA Review of TAR-200 in Bladder Cancer
The New Brunswick, N.J., pharmaceutical giant on Thursday said the application covers TAR-200 for the treatment of patients with Bacillus Calmette-Guerin-unresponsive high-risk non-muscle invasive ...